Jonathan M. DeLiberty

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

G. Aaron Hobbs, Nicole M. Baker, Anne M. Miermont et al. · Cancer Discovery · 2019 · 226 citations · Full text

Medicine, Genetics, Oncology +12

Functional and biological heterogeneity of KRAS ^Q61 mutations

Minh V. Huynh, G. Aaron Hobbs, Antje Schaefer et al. · Science Signaling · 2022 · 46 citations · Full text

Medicine, Genetics, Molecular Genetics +9

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

Jennifer E. Klomp, Ye S. Lee, Craig M. Goodwin et al. · Cell Reports · 2021 · 42 citations · Full text

Medicine, Molecular Biology, Oncology +16

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Rochelle Fletcher, Jingshan Tong, Denise Risnik et al. · Oncogene · 2021 · 32 citations · Full text

Medicine, Immunology, Oncology +16

Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer

Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker et al. · Cancer Research · 2025 · 18 citations · Full text

Life Sciences, Oncology, Pharmacology +17